|
CN110996993A
|
|
Immunogenic compositions comprising fusion peptides derived from superantigen toxoids
|
|
CN110913883A
|
|
Immunogenic composition comprising Staphylococcus aureus leukocidin LUKA and LUKB derived polypeptides
|
|
CN110087677A
|
|
The extensive neutralizing antibody of fusion ring inside targeting Ebola virus glycoprotein
|
|
WO2017172622A1
|
|
Pan filovirus vaccine compositions and methods of making
|
|
WO2017156423A2
|
|
Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
|
|
WO2016145385A2
|
|
Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
|
|
MX2017009698A
|
|
Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases.
|
|
WO2016112065A1
|
|
Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
|
|
US2017334973A1
|
|
Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins
|
|
US2017158753A1
|
|
Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
|
|
EP3094348A1
|
|
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
|
|
WO2014205111A1
|
|
Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
|
|
NZ626762A
|
|
Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
|
|
WO2012109167A1
|
|
Immunogenic composition comprising alpha-hemolysin oligopeptides
|
